Cybin Completes $34 Million Bought Deal Offering
On February 4, 2021, Cybin Inc. (NEO: CYBN) (the “Company”), a biotechnology company focused on progressing psychedelic therapeutics, completed a bought deal short form prospectus offering. In connection with the offering, the Company issued 15,246,000 units (“Units”) at a price of $2.25 per Unit for aggregate gross proceeds of $34,303,500. Each Unit consisted of one common share and one half of one common share purchase warrant of the Company.
Cybin intends to use the net proceeds from the offering to advance its clinical trials, novel molecule programs and technologies surrounding the patient experience, and for working capital and general corporate purposes.
Aird & Berlis acted for Cybin with a team that included Sherri Altshuler, Melanie Cole, Danny Kharazmi, Russell Sanders, Sean Green and Meredith McCann (Capital Markets/M&A) and Barbara Worndl (Tax).
-
BioFull bio
Sherri earns the trust of her clients by adeptly managing complex and time-sensitive corporate finance transactions and by providing relevant, busines...
-
BioFull bio
Whether advising her clients on public and private financings, mergers and acquisitions or corporate commercial matters, Melanie takes a client-first ...
-
BioFull bio
Danny thrives on finding effective and creative solutions to help clients navigate through highly-regulated industries.
-
BioFull bio
Russell is a corporate lawyer who enjoys connecting with clients to build long-lasting relationships.
-
BioFull bio
When it comes to complex capital markets transactions, Sean provides clients with the support they need to navigate corporate laws and achieve their b...
-
BioFull bio
When it comes to complex capital markets transactions or navigating regulatory requirements, Meredith’s primary focus is on her clients’ i...
-
BioFull bio
Clients appreciate Barbara’s dedication to finding the most tax efficient structures for their business. She thrives on the complexities of tax ...
